ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Scientists Lobby For Funding Increase. DuBois To Leave Vanderbilt For M.D. Anderson.

January 12, 2007

FDA Invites Ad Hoc Consumer Reps To ODAC Meetings

February 17, 1995

NCI Advisory Group, Other Cancer Meetings

January 30, 1976

In Brief: NCAB Lacked Courage On Some Special Actions, Amos Says; Pick Reviewers On Ability Only, Scientist Asks

July 30, 1982

NCI Publishes New Atlas Of Cancer Mortality

December 10, 1999

Opioid Pain Reliever Approved With Risk Reduction Plan

July 31, 2009